WallStSmart

Evotec SE ADR (EVO)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 1791% more annual revenue ($14.30B vs $756.33M). EVO leads profitability with a -21.0% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.14. VTRS earns a higher WallStSmart Score of 50/100 (C-).

EVO

Hold

38

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 4.8
Piotroski: 3/9Altman Z: 0.42

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVO1 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

EVO4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$902.78M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-18.0%2/10

ROE of -18.0% — below average capital efficiency

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : EVO

The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : EVO

The primary concerns for EVO are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

EVO carries more volatility with a beta of 1.12 — expect wider price swings.

VTRS is growing revenue faster at 5.0% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (50/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evotec SE ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Evotec SE is a leading global biotechnology company based in Hamburg, Germany, renowned for its comprehensive drug discovery and development solutions tailored for the pharmaceutical and biotech industries. The firm utilizes a collaborative model, partnering with various stakeholders—ranging from established pharmaceutical companies to innovative academic institutions—to propel the advancement of therapeutic programs across numerous modalities, including small molecules, biologics, and cell therapies. With a robust pipeline of projects and a steadfast focus on enhancing patient outcomes, Evotec is well-positioned to capitalize on emerging opportunities in the biopharmaceutical sector, solidifying its pivotal role in driving healthcare innovation.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?